HealthStream (HSTM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Achieved record Q2 2026 revenues of $83.7 million, up 12.5% year-over-year, with adjusted EBITDA of $20.6 million, up 16.9%, and net income of $6.7 million, up 23.8%.
Growth was driven by organic expansion and contributions from recent acquisitions, notably Virsys12 and MissionCare Collective.
Diluted EPS was $0.23, up from $0.18 in Q2 2025.
Board declared a quarterly cash dividend of $0.035 per share.
96–97% of revenues are subscription-based, providing high predictability and recurring revenue.
Financial highlights
Subscription product revenues grew by $8 million (11.2%), professional services by $1.3 million (52.6%) year-over-year.
Operating income for Q2 2026 was $8.3 million, up 41.4% year-over-year.
Adjusted EBITDA for the first half was $40.7 million, up 20.4% year-over-year.
Cash, cash equivalents, and marketable securities totaled $66.7 million at June 30, 2026; no outstanding debt.
Free cash flow for the first half was $24.7 million, up 73% year-over-year.
Outlook and guidance
Updated 2026 revenue guidance to $327–$332 million, net income guidance to $19.5–$22.2 million, and adjusted EBITDA to $74–$78 million.
Capital expenditures guidance: $31.0–$34.0 million.
Guidance assumes stable economic conditions and excludes future acquisitions or asset impairments.
Q3 revenue growth expected at ~8%, with adjusted EBITDA margin at ~22%.
Management expects continued financial pressures among healthcare customers due to legislative and regulatory changes.
Latest events from HealthStream
- Record Q1 2026 revenue and profit growth, driven by acquisitions and strong liquidity.HSTM
Q1 2026 - Shareholders will vote virtually on directors, auditor ratification, and executive pay, focusing on governance and ESG.HSTM
Proxy filing - Virtual annual meeting to vote on directors, auditor, and executive pay set for May 28, 2026.HSTM
Proxy filing - Record 2025 revenue and EBITDA growth, with 2026 guidance projecting further expansion.HSTM
Q4 2025 - 2025 proxy covers director elections, auditor ratification, executive pay, and ESG priorities.HSTM
Proxy Filing - Annual meeting to address director elections, pay, and auditor ratification.HSTM
Proxy Filing - Record Q3 revenue, profit growth, and raised guidance reflect strong operational momentum.HSTM
Q3 2024 - Q2 2024 revenue up 3.4% to $71.6M, guidance reaffirmed, and SaaS platform growth continues.HSTM
Q2 2024 - Strong SaaS growth, acquisitions, and platform innovation drive robust 2024 results and 2025 outlook.HSTM
Q4 2024